[go: up one dir, main page]

UY30293A1 - ORAL DOSAGE FORMULATIONS OF PROTEASE RESISTANT POLYPEPTIDES AND USES OF THE SAME FOR TREATMENT - Google Patents

ORAL DOSAGE FORMULATIONS OF PROTEASE RESISTANT POLYPEPTIDES AND USES OF THE SAME FOR TREATMENT

Info

Publication number
UY30293A1
UY30293A1 UY30293A UY30293A UY30293A1 UY 30293 A1 UY30293 A1 UY 30293A1 UY 30293 A UY30293 A UY 30293A UY 30293 A UY30293 A UY 30293A UY 30293 A1 UY30293 A1 UY 30293A1
Authority
UY
Uruguay
Prior art keywords
dosage formulations
oral dosage
treatment
same
protease resistant
Prior art date
Application number
UY30293A
Other languages
Spanish (es)
Inventor
Vega Manuel
Drittanti Lila
Chauchard Caroline
Borrelly Gilles
Original Assignee
Nautilus Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/658,834 external-priority patent/US7611700B2/en
Application filed by Nautilus Biotech filed Critical Nautilus Biotech
Publication of UY30293A1 publication Critical patent/UY30293A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporciona formulaciones de dosificacion oral de polipéptidos terapéuticos resistentes a proteasas. Las formulaciones de dosificacion para administracion por dosis y por DIA o por semana son mayores que la dosificacion subcutánea. Se incluye entre las formulaciones de dosificacion oral tabletas y cápsulas, incluyendo formas con recubrimiento entérico. Se proporciona métodos para el tratamiento y prevencion de enfermedades o condiciones que son tratables o prevenibles mediante la administracion de tales formulaciones de dosificacion oral de polipéptidos resistentes a las proteasas.Oral dosage formulations of protease-resistant therapeutic polypeptides are provided. Dosage formulations for administration by dose and by DAY or by week are greater than subcutaneous dosing. Tablets and capsules, including enteric coated forms, are included in the oral dosage formulations. Methods are provided for the treatment and prevention of diseases or conditions that are treatable or preventable by administering such oral dosage formulations of protease resistant polypeptides.

UY30293A 2003-09-08 2007-04-18 ORAL DOSAGE FORMULATIONS OF PROTEASE RESISTANT POLYPEPTIDES AND USES OF THE SAME FOR TREATMENT UY30293A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/658,834 US7611700B2 (en) 2002-09-09 2003-09-08 Protease resistant modified interferon alpha polypeptides

Publications (1)

Publication Number Publication Date
UY30293A1 true UY30293A1 (en) 2007-10-31

Family

ID=38779828

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30293A UY30293A1 (en) 2003-09-08 2007-04-18 ORAL DOSAGE FORMULATIONS OF PROTEASE RESISTANT POLYPEPTIDES AND USES OF THE SAME FOR TREATMENT

Country Status (1)

Country Link
UY (1) UY30293A1 (en)

Similar Documents

Publication Publication Date Title
ECSP21051833A (en) COMBINATION OF DEXTROMETORPHAN AND BUPROPION FOR THE TREATMENT OF DEPRESSION
UY35624A (en) USE OF HIGH DOSE PRIDOPIDINE TO TREAT HUNTINGTON'S DISEASE
ATE306266T1 (en) IMPROVED ADMINISTRATION TECHNOLOGY FOR MULTIPLE MEDICATION DOSAGE
ECSP034869A (en) A COMPOSITION FOR THE SKIN, PERMEABLE SELECTIVE INHIBITOR OF CICLOOXIGENASA-2
NO993520L (en) Dosage forms and methods for better erectile dysfunction
CR8352A (en) PHARMACEUTICAL FORMULATIONS, PROCEDURES AND DOSAGE GUIDELINES FOR THE TREATMENT AND PREVENTION OF ACUTE CORONARY SYNDROMES
EA200401317A1 (en) COMPOSITIONS AND METHODS OF LIPOS DOSING OF CERTAIN DIMENSIONS FOR THE TREATMENT OR PREVENTION OF DISEASE
TW200738228A (en) Neramexane modified release matrix tablet
PE20150161A1 (en) USE OF HIGH DOSE LAQUINIMOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS
RU2008119454A (en) MEDICINE FOR PROTECTION OF MOTOR NEURON IN PATIENTS WITH LATERAL AMYOTROPHIC SCLEROSIS
NO20071044L (en) Dosage forms with enterally coated tablet cores
AR025938A1 (en) NEW PHARMACEUTICAL COMPOSITIONS.
AR046036A1 (en) RISEDRONATE COMPOSITIONS AND METHODS FOR USE
ECSP078014A (en) DOSAGE REGIME FOR PRASUGREL
PL1656131T3 (en) Use of betaine for treating intermittent claudication
SE0401612L (en) Inhaler using tub
PH12019502767A1 (en) Oral pharmaceutical formulations of remogliflozin
AR048318A1 (en) ORAL MATRIX FORMULATIONS THAT INCLUDE LICARBAZEPINA
PA8549401A1 (en) COMPLEX THAT INCLUDES INHIBITING FACTOR OF OSTEOCLASTOGENESIS AND POLISACARIDO
UY30293A1 (en) ORAL DOSAGE FORMULATIONS OF PROTEASE RESISTANT POLYPEPTIDES AND USES OF THE SAME FOR TREATMENT
MA31227B1 (en) PHARMACEUTICAL COMPOSITION COMPRISING PHLOROGLUCINOL AND PARACETAMOL.
AR060531A1 (en) ORAL DOSAGE FORMULATIONS OF PROTEASE RESISTANT POLYPEPTIDES AND USES OF THE SAME FOR TREATMENT
ES2572180T3 (en) Controlled release formulations comprising discrete uncoated unit (s) and a prolonged release matrix
DOP2022000004A (en) PHARMACEUTICAL COMPOSITIONS RESISTANT TO THE DISCHARGE OF DOSES THAT INCLUDE VENIRUNAD
BR112018009476A8 (en) plasminogen dosage regimen for wound healing

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170606